Efficacy of Sitagliptine on Bone and Mineral Metabolism:S-BMM study

Efficacy of Sitagliptine on Bone and Mineral Metabolism:S-BMM study - effects of sitagliptin on bone

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019867

Enrollment

100

Registered

2015-11-20

Start date

2012-02-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 diabetes mellitus

Interventions

sitagliptin 50 mg other oral glucose-lowering agents

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The study subjects were patients with type 2 diabetes mellitus whose hemoglobin A1c (HbA1c) was lower than 8.4% (according to the National Glycohaemoglobin Standardisation Programme [NGSP]) despite treatment with pioglitazone (15-30 mg/day) for at least 6 months, aged <80 years, who received treatment at the Outpatient Department of the University of Occupational and Environmental Health Hospital or its affiliated hospitals.

Exclusion criteria

Exclusion criteria: Patients with a history of ketoacidosis, patients with type 1 diabetes, patients with nephropathy (serum creatinine: males >1.5 mg/dL females >1.3 mg/dL), patients treated with insulin, and women who were possibly pregnant were excluded from the study.

Design outcomes

Primary

Measure	Time frame
The primary outcome was changes in BAP at 6 months.	—

Countries

Japan

Contacts

Public ContactHiroko Mori

University of Occupational and Environmental Health First Department of Internal Medicine, School of Medicine

morihiro@med.uoeh-u.ac.jp+8100936031611

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026